Peptide FDA Compounding Status Tracker 2026 — Complete 503A Guide

1Key Upcoming PCAC & Regulatory Dates

The PCAC has scheduled the following hearings to review peptides currently in Category 2. These dates determine whether each peptide will be approved for 503A compounding or removed from pharmacy access. Mark your calendar.

1. July 23, 2026Imminent
   PCAC Meeting — Day 1

   Four high-profile peptides face the committee. Public comment period open through July 9.

   BPC-157KPVMOTs-CTB-500
2. July 24, 2026Upcoming
   PCAC Meeting — Day 2

   Three additional peptides reviewed on the second day of the hearing.

   Emideltide (DSIP)EpitalonSemax
3. Before February 2027Announced
   Second PCAC Meeting — Additional Peptides

   FDA has announced a second PCAC meeting to review five more peptides for possible 503A inclusion. LL-37, Dihexa, Melanotan II, and PEG-MGF were previously withdrawn with no active review — now reconsidered. Exact date TBD (before the end of February 2027).

   Cathelicidin LL-37GHK-CuDihexa AcetateMelanotan IIPEG-MGF

2Peptides Under FDA Review — Full Status Table

All peptides currently under FDA review for 503A compounding eligibility. Use the color-coded badges to identify each peptide’s review stage. Category 2 → PCAC peptides are listed first, followed by Category 1 peptides still under standard evaluation.

← Scroll to see all columns →

3Understanding FDA 503A Categories

The FDA uses a category system to organize bulk drug substances nominated for compounding under Section 503A. Here’s what each means for peptide access.

What does “Approved for 503A Compounding” mean?

When a substance is approved for 503A compounding, licensed pharmacies can legally prepare customized formulations for individual patients with a valid prescription. This is distinct from FDA-approved manufactured drugs — compounded medications are not FDA-approved products themselves, but are prepared under the framework governing pharmacy compounding. Approval ensures adequate safety, quality, and clinical evidence exists to support the substance’s use in patient care.

How PCAC hearings work

The PCAC follows a structured process: the FDA presents its safety and clinical review; public stakeholders submit testimony; and committee members discuss and vote on a recommendation. The FDA is not bound by PCAC recommendations but historically follows them in the majority of cases. Final determinations are typically issued weeks to months after the vote.

4What This Means for Patients

If you’re using — or considering — peptide therapy, here’s how to protect your access to care as the regulatory landscape evolves.

• ✓If you’re currently using a peptide on this list, don’t panic. Category 1 peptides remain available through compounding pharmacies while under evaluation. For Category 2 / PCAC-scheduled peptides, talk to your prescriber about your options before the hearing date.
• ✓Work only with legitimate 503A compounding pharmacies — state-licensed, FDA-registered pharmacies that compound pursuant to valid prescriptions. Avoid unregulated “research chemical” suppliers. Find a compounding pharmacy →
• ✓Always work with a licensed prescribing provider. Peptide therapy requires medical oversight — lab monitoring, dosage adjustments, and follow-up — to ensure it’s safe and appropriate for you. Consult a peptide specialist →
• ✓PCAC outcomes are not final until the FDA acts. Even after a recommendation, the FDA must issue a formal determination — there’s often a window between the hearing and final action where substances remain accessible.
• ✓Engage in the public comment process. If a peptide you depend on is scheduled for review, submit a public comment to the FDA docket — patient testimonials carry weight. Check regulations.gov for open comment periods.

5In-Depth FDA Peptide Articles

Go deeper on specific peptides, PCAC mechanics, and what the 2026 decisions mean for patients and providers.

6Frequently Asked Questions

• What is FDA 503A Category 1 for peptides?

  Category 1 substances are currently under evaluation by the FDA. While under review, these peptides can still be legally compounded by registered 503A pharmacies under a valid prescription. Category 1 status does not imply safety concerns — it simply means the FDA has not yet completed its review.

• What is FDA 503A Category 2 for peptides?

  Category 2 substances have been flagged with potential safety or quality concerns. Compounding of these substances is restricted while they undergo further review by the Pharmacy Compounding Advisory Committee (PCAC). A PCAC hearing must take place before a final determination is made.

• What is the PCAC and how does it affect peptide access?

  The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that reviews nominated bulk drug substances for use in compounding. The PCAC holds public hearings, reviews clinical evidence, and makes recommendations to the FDA on whether substances should be approved for 503A compounding. Their recommendations heavily influence final FDA decisions on peptide availability.

• Can I still get compounded peptides in 2026?

  Yes. Many peptides remain available through legitimate 503A compounding pharmacies under a valid prescription while they are under FDA evaluation (Category 1). Peptides in Category 2 or under active PCAC safety review may have restricted availability. Always work with a licensed prescribing provider and a registered compounding pharmacy.

• What happens after PCAC reviews a peptide?

  After the PCAC hearing, the committee makes a recommendation to the FDA. The FDA then issues a final determination: the peptide is either approved for 503A compounding (added to the approved bulk substances list) or denied. If denied, compounding pharmacies must stop producing the substance. The FDA's decision typically follows within weeks to months after the PCAC recommendation.